clinical trial · NCT05305560
A Study to Evaluate the Efficacy and Safety of Ivermectin in COVID-19 Prevention
MedinCell S.A·phase2·completed·n = 400
COVID-19Ivermectin TabletsMatching placebo tablets
brief summary
A multicenter, randomized, double-blind, placebo-controlled, study to evaluate the efficacy and safety of oral ivermectin tablets versus placebo for COVID-19 prophylaxis
started
Mar 25, 2022
primary completion
Sep 15, 2022
completion
Oct 13, 2022
last updated
Dec 31, 2024
detailed description
This trial comprises a total observation period of up to 56 days (an on-treatment period of up to 28 days and a safety follow-up of up to 28 days).
official title
A Multicentre Randomised, Double-Blind, Placebo-controlled, Study to Evaluate the efficAcy and Safety of Oral IVErmectin Tablets in the Prevention of COVID-19
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol